Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA

Stem Cell Research

Volumn 13, Issue 3, 2014, Pages 693-704

  Lui, Kathy O ^a   Zangi, Lior ^a,b   Chien, Kenneth R ^a,c  

^a Harvard University   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VASCULOTROPIN 165; SIGNAL PEPTIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL REGENERATION; CELL THERAPY; ENDOTHELIUM CELL; HEART MUSCLE CELL; HEART REGENERATION; HUMAN; IN VIVO STUDY; PARACRINE SIGNALING; REVIEW; RNA REPLICATION; STEM CELL; TISSUE REGENERATION; ANIMAL; CYTOLOGY; GENE TRANSFER; GENETICS; HEART; METABOLISM; PATHOPHYSIOLOGY; REGENERATION; STEM CELL TRANSPLANTATION;

ANIMALS; GENE TRANSFER TECHNIQUES; HEART; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; REGENERATION; RNA, MESSENGER; STEM CELL TRANSPLANTATION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911418614     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2014.06.007     Document Type: Review

References (99)

1. Abdel-Latif A., et al. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am. Heart J. 2008, 156:216-226. e219. 10.1016/j.ahj.2008.03.024.
2. Addis R.C., Epstein J.A. Induced regeneration-the progress and promise of direct reprogramming for heart repair. Nat. Med. 2013, 19:829-836. 10.1038/nm.3225.
3. Armstrong E.J., Rutledge J.C., Rogers J.H. Coronary artery revascularization in patients with diabetes mellitus. Circulation 2013, 128:1675-1685. 10.1161/CIRCULATIONAHA.113.002114.
4. Balsam L.B., et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004, 428:668-673. 10.1038/nature02460.
5. Beltrami A.P., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114:763-776.
6. Bolli R., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857. 10.1016/S0140-6736(11)61590-0.
7. Botta R., et al. Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J. 2004, 18:1392-1394. 10.1096/fj.03-0879fje.
8. Braitsch C.M., Kanisicak O., van Berlo J.H., Molkentin J.D., Yutzey K.E. Differential expression of embryonic epicardial progenitor markers and localization of cardiac fibrosis in adult ischemic injury and hypertensive heart disease. J. Mol. Cell. Cardiol. 2013, 65:108-119. 10.1016/j.yjmcc.2013.10.005.
9. Brissova M., et al. Islet microenvironment, modulated by vascular endothelial growth factor-A signaling promotes beta cell regeneration. Cell Metab. 2014, 19:498-511. 10.1016/j.cmet.2014.02.001.
10. Bu L., et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009, 460:113-117. 10.1038/nature08191.
11. Cai J., et al. Transplantation of embryonic stem cell-derived cardiomyocytes improves cardiac function in infarcted rat hearts. Cytotherapy 2007, 9:283-291. 10.1080/14653240701247838.
12. Cai C.L., et al. A myocardial lineage derives from Tbx18 epicardial cells. Nature 2008, 454:104-108. 10.1038/nature06969.
13. Cai L., et al. IFATS collection: human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem Cells 2009, 27:230-237. 10.1634/stemcells.2008-0273.
14. Carmeliet P., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 1999, 5:495-502. 10.1038/8379.
15. Carvalheira J.B., Qiu Y., Chawla A. Blood spotlight on leukocytes and obesity. Blood 2013, 122:3263-3267. 10.1182/blood-2013-04-459446.
16. Caspi O., et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J. Am. Coll. Cardiol. 2007, 50:1884-1893. 10.1016/j.jacc.2007.07.054.
17. Chimenti I., et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 2010, 106:971-980. 10.1161/CIRCRESAHA.109.210682.
18. Chong J.J., et al. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell 2011, 9:527-540. 10.1016/j.stem.2011.10.002.
19. Chong J.J., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014, 510:273-277. 10.1038/nature13233.
20. Chugh A.R., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012, 126:S54-64. 10.1161/CIRCULATIONAHA.112.092627.
21. Ding B.S., et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010, 468:310-315. 10.1038/nature09493.
22. Ding B.S., et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 2011, 147:539-553. 10.1016/j.cell.2011.10.003.
23. Ellison G.M., et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 2013, 154:827-842. 10.1016/j.cell.2013.07.039.
24. Formiga F.R., et al. Angiogenic therapy for cardiac repair based on protein delivery systems. Heart Fail. Rev. 2012, 17:449-473. 10.1007/s10741-011-9285-8.
25. Fu J.D., et al. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Reports 2013, 1:235-247. 10.1016/j.stemcr.2013.07.005.
26. Gao R., et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 2010, 55:1907-1914. 10.1016/j.jacc.2009.12.044.
27. Gao J., et al. A myocardial patch made of collagen membranes loaded with collagen-binding human vascular endothelial growth factor accelerates healing of the injured rabbit heart. Tissue Eng. A 2011, 17:2739-2747. 10.1089/ten.TEA.2011.0105.
28. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103:1204-1219. 10.1161/CIRCRESAHA.108.176826.
29. Green E.M., Lee R.T. Proteins and small molecules for cellular regenerative medicine. Physiol. Rev. 2013, 93:311-325. 10.1152/physrev.00005.2012.
30. Groopman J.E., Molina J.M., Scadden D.T. Hematopoietic growth factors. Biology and clinical applications. N. Engl. J. Med. 1989, 321:1449-1459. 10.1056/NEJM198911233212106.
31. Hedman M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683. 10.1161/01.CIR.0000070540.80780.92.
32. Hendel R.C., et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000, 101:118-121.
33. Henry T.D., et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003, 107:1359-1365.
34. Herrmann F., Bundschu K., Kuhl S.J., Kuhl M. Tbx5 overexpression favors a first heart field lineage in murine embryonic stem cells and in Xenopus laevis embryos. Dev. Dyn. 2011, 240:2634-2645. 10.1002/dvdy.22776.
35. Hinkel R., Trenkwalder T., Kupatt C. Gene therapy for ischemic heart disease. Expert. Opin. Biol. Ther. 2011, 11:723-737. 10.1517/14712598.2011.570749.
36. Hsieh P.C., et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat. Med. 2007, 13:970-974. 10.1038/nm1618.
37. Ieda M., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386. 10.1016/j.cell.2010.07.002.
38. Jabbour A., et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur. J. Heart Fail. 2011, 13:83-92. 10.1093/eurjhf/hfq152.
39. Kajstura J., et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res. 2005, 96:127-137. 10.1161/01.RES.0000151843.79801.60.
40. Kariko K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175. 10.1016/j.immuni.2005.06.008.
41. Kariko K., Muramatsu H., Ludwig J., Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011, 39:e142. 10.1093/nar/gkr695.
42. Kormann M.S., et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011, 29:154-157. 10.1038/nbt.1733.
43. Laugwitz K.L., et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005, 433:647-653. 10.1038/nature03215.
44. Li F., Wang X., Capasso J.M., Gerdes A.M. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J. Mol. Cell. Cardiol. 1996, 28:1737-1746. 10.1006/jmcc.1996.0163.
45. Limana F., et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ. Res. 2005, 97:e73-e83. 10.1161/01.RES.0000186276.06104.04.
46. Lin Y.D., et al. Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair. Sci. Transl. Med. 2012, 4:146ra109. 10.1126/scitranslmed.3003841.
47. Loffredo F.S., Steinhauser M.L., Gannon J., Lee R.T. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011, 8:389-398. 10.1016/j.stem.2011.02.002.
48. Loffredo F.S., et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013, 153:828-839. 10.1016/j.cell.2013.04.015.
49. Losordo D.W., et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998, 98:2800-2804.
50. Lui KO S.M., Lieu D.K., Li R.A., Bu L. Induced pluripotent stem cells as a disease model for studying inherited arrhythmias: promises and hurdles. Drug Discovery Today 2013, 9:e199-e207.
51. Lui K.O., Bu L., Li R.A., Chan C.W. Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives. Birth Defects Res. C Embryo Today 2012, 96:98-108. 10.1002/bdrc.21004.
52. Lui K.O., et al. Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res. 2013, 23:1172-1186. 10.1038/cr.2013.112.
53. Makkar R.R., et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012, 379:895-904. 10.1016/S0140-6736(12)60195-0.
54. Malliaras K., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J. Am. Coll. Cardiol. 2014, 63:110-122. 10.1016/j.jacc.2013.08.724.
55. Malliaras K., et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. EMBO Mol. Med 2014, 10.1002/emmm.201303626.
56. Mandal P.K., Rossi D.J. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat. Protoc. 2013, 8:568-582. 10.1038/nprot.2013.019.
57. Matsa E., Sallam K., Wu J.C. Cardiac stem cell biology: glimpse of the past, present, and future. Circ. Res. 2014, 114:21-27. 10.1161/CIRCRESAHA.113.302895.
58. Moretti A., et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006, 127:1151-1165. 10.1016/j.cell.2006.10.029.
59. Murry C.E., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004, 428:664-668. 10.1038/nature02446.
60. Nagy J.A., Dvorak A.M., Dvorak H.F. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb. Perspect. Med. 2012, 2:a006544. 10.1101/cshperspect.a006544.
61. Naqvi N., et al. A proliferative burst during preadolescence establishes the final cardiomyocyte number. Cell 2014, 157:795-807. 10.1016/j.cell.2014.03.035.
62. Nemir M., et al. The Notch pathway controls fibrotic and regenerative repair in the adult heart. Eur. Heart J 2012, 10.1093/eurheartj/ehs269.
63. Nowbar A.N., et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 2014, 348:g2688. 10.1136/bmj.g2688.
64. Porrello E.R., et al. Transient regenerative potential of the neonatal mouse heart. Science 2011, 331:1078-1080. 10.1126/science.1200708.
65. Ptaszek L.M., Mansour M., Ruskin J.N., Chien K.R. Towards regenerative therapy for cardiac disease. Lancet 2012, 379:933-942. 10.1016/S0140-6736(12)60075-0.
66. Qian L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598. 10.1038/nature11044.
67. Qyang Y., et al. The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell 2007, 1:165-179. 10.1016/j.stem.2007.05.018.
68. Rutanen J., et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004, 109:1029-1035. 10.1161/01.CIR.0000115519.03688.A2.
69. Sanganalmath S.K., Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 2013, 113:810-834. 10.1161/CIRCRESAHA.113.300219.
70. Sato K., et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J. Am. Coll. Cardiol. 2001, 37:616-623.
71. Schwarz E.R., et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J. Am. Coll. Cardiol. 2000, 35:1323-1330.
72. Segers V.F., et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692. 10.1161/CIRCULATIONAHA.107.718718.
73. Silva G.V., et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005, 111:150-156. 10.1161/01.CIR.0000151812.86142.45.
74. Silverberg D.S., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 2001, 37:1775-1780.
75. Simons M., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105:788-793.
76. Simon-Yarza T., et al. Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics 2012, 2:541-552. 10.7150/thno.3682.
77. Smart N., et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 2011, 474:640-644. 10.1038/nature10188.
78. Smith R.R., et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007, 115:896-908. 10.1161/CIRCULATIONAHA.106.655209.
79. Soiffer R.J. Hematopoietic Stem Cell Transplantation 2008, Humana Press.
80. Stamm C., et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J. Thorac. Cardiovasc. Surg. 2007, 133:717-725. 10.1016/j.jtcvs.2006.08.077.
81. Stewart D.J., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006, 13:1503-1511. 10.1038/sj.gt.3302802.
82. Stewart D.J., et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther. 2009, 17:1109-1115. 10.1038/mt.2009.70.
83. Taylor D.A., et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 1998, 4:929-933.
84. Tritos N.A., Danias P.G. Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta-analysis. Endocr. Pract. 2008, 14:40-49. 10.4158/EP.14.1.40.
85. Valina C., et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur. Heart J. 2007, 28:2667-2677. 10.1093/eurheartj/ehm426.
86. van Berlo J.H., et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014, 509:337-341. 10.1038/nature13309.
87. Voo S., Eggermann J., Dunaeva M., Ramakers-van Oosterhoud C., Waltenberger J. Enhanced functional response of CD133+ circulating progenitor cells in patients early after acute myocardial infarction. Eur. Heart J. 2008, 29:241-250. 10.1093/eurheartj/ehm542.
88. Vose J.M., Armitage J.O. Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 1995, 13:1023-1035.
89. Vunjak-Novakovic G., Lui K.O., Tandon N., Chien K.R. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu. Rev. Biomed. Eng. 2011, 13:245-267. 10.1146/annurev-bioeng-071910-124701.
90. Wang X., et al. The role of the sca-1+/CD31- cardiac progenitor cell population in postinfarction left ventricular remodeling. Stem Cells 2006, 24:1779-1788. 10.1634/stemcells.2005-0386.
91. Wang J., et al. Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ. Res. 2010, 106:1904-1911. 10.1161/CIRCRESAHA.110.221762.
92. Warren L., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630. 10.1016/j.stem.2010.08.012.
93. Wright M.J., et al. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res. Cardiol. 2001, 96:227-236.
94. Wu J., et al. Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials 2011, 32:579-586. 10.1016/j.biomaterials.2010.08.098.
95. Xu H., et al. Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature. Cell Res. 2012, 22:142-154. 10.1038/cr.2011.171.
96. Yang R., et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002, 39:815-820.
97. Zangi L., et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 2013, 31:898-907. 10.1038/nbt.2682.
98. Zhou B., et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 2008, 454:109-113. 10.1038/nature07060.
99. Zhou B., et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J. Clin. Invest. 2011, 121:1894-1904. 10.1172/JCI45529.